maravai lifesciences holdings glp-1 receptor agonist medications Harnessing Agonists for Obesity Treatment: Prospects and Obstacles on the Horizon Beyond GLP-1: the next wave
Description
Currently, 25% of adults in the United Kingdom are living with obesity and the rise in obesity has significantly increased the number of patients with T2DM [4,5,6]
Although the cardiovascular safety of tirzepatide has been established in short-term trials [170], proof of beneficial effects on hard cardiovascular outcomes is still awaited with dedicated outcome trials ongoing (SURPASS-CVOT, NCT04255433
Figure 3: Sequelae of Diabetes Mellitus Type 2 and Obesity provides an overview of the conditions associated with diabetes and obesity
[DOI] [PMC free article] [PubMed] [Google Scholar] 85.Patel A., MacMahon S., Chalmers J., Neal B., Billot L., Woodward M., Marre M., Cooper M., Glasziou P., Grobbee D., et al
doi: 10.3389/fendo.2022.1004044 [DOI] [PMC free article] [PubMed] [Google Scholar] 4.Doyle ME, Theodorakis MJ, Holloway HW, Bernier M, Greig NH, Egan JM
These results give us a direction that GLP-1RAs, currently used for diabetes, may be an alternative drug for the treatment of osteoporosis
